Genzyme is joining Ablynx’ partner list, which already includes AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Sanofi subsidiary now wants to try out the Nanobody technology of Ablynx against a target at the origin of multiple sclerosis.
Genzyme wants to investigate nanobodies against a target that specifically aligns with Genzyme’s early-stage multiple sclerosis research programs involving neuroprotection and central nervous system repair. The neurodegeneration observed in multiple sclerosis is not directly targeted by existing treatments and with the single-domains antibodies developed by Ablynx, Genzyme is expecting to answer a pressing medical need.
Under the terms of the agreement, Genzyme will have the right to perform in vitro and in vivo research with Ablynx’s Nanobodies in preclinical studies in return of an exclusivity fee. After completion of these studies, Genzyme will have the possibility to negotiate a license agreement. According to Ablynx, the Nanobodies have already shown promising results against the specific target of interest and confirmed their activity in pre-clinical models.
The Nanobody technology platform aims at creating new single variable domain antibodies derived from the llama immune-system.